Tri Locum Partners’s Cardiff Oncology CRDF Stock Holding History

Tri Locum Partners’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-157,403	Closed	-$2.83M	–	50
2020 Q4	$2.83M	Buy	+157,403	New	+$2.77M	1.03%	27

Other funds holding CRDF

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Tri Locum Partners's CRDF Position: Q1 2021 in Review

Tri Locum Partners sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 157,403 shares — an estimated $2.83M sold.

Tri Locum Partners first reported a position in CRDF in Q4 2020 and held it in 1 quarter. The position peaked at $2.83M in Q4 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

Tri Locum Partners reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
Tri Locum Partners sold 157,403 Cardiff Oncology shares in Q1 2021, an estimated $2.83M.
Tri Locum Partners first reported a position in Cardiff Oncology in Q4 2020 and held it in 1 quarter.
Tri Locum Partners's Cardiff Oncology position peaked at $2.83M in Q4 2020.
73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.